clozapine (Rx)

Brand and Other Names:Clozaril, Versacloz
  • Print

Dosing & Uses

AdultPediatricGeriatric

Dosage Forms & Strengths

tablet

  • 25mg
  • 50mg
  • 100mg
  • 200mg

oral suspension (Versacloz)

  • 50mg/mL

Schizophrenia

Indicated for reducing risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder in patients who are judged to be at chronic risk to re-experience suicidal behavior

Also indicated for treatment-resistant schizophrenia in patients who fail to respond adequately to standard antipsychotic treatment

12.5 mg PO once daily or q12hr initially; increase in increments of 25-50 mg/day, if well tolerated, to achieve target dosage of 300-450 mg/day (administered in divided doses) by end of 2 weeks

Subsequently, may increase dose once or twice weekly in increments of up to 100 mg; not to exceed 900 mg/day

Maintenance: Generally, patients who respond should continue maintenance treatment on their effective dose beyond the acute episode

Reinitiation of therapy

  • If therapy interrupted for ≥48 hr, must reinitiate dose at 12.5 mg qDay or BID to minimize risk of hypotension, bradycardia, and syncope; if dose well tolerated, may increase more rapidly than with initial titration, unless cardiopulmonary arrest occurred during initial titration, then titrate with extreme caution

Discontinuation of therapy

  • Method of treatment discontinuation depends on patient’s last ANC
  • Reduce dose gradually over a period of 1-2 weeks if termination not related to neutropenia; taper gradually to avoid withdrawal symptoms and minimize risk of relapse; for schizophrenia, guidelines recommend gradual taper over 6-24 months (American Psychiatric Association guidelines recommend reducing dose 10% each month)
  • For abrupt clozapine discontinuation for a reason unrelated to neutropenia, continue existing ANC monitoring until ANC is ≥1500/mm3
  • If benign patient has benign ethnic neutropenia (BEN); monitor until ANC is ≥1000/mm3 or above baseline
  • Additional ANC monitoring required for onset of fever during the 2 weeks after discontinuation
  • Monitor all patients carefully for the recurrence of psychotic symptoms and symptoms related to cholinergic rebound (eg, profuse sweating, headache, nausea, vomiting, diarrhea)

Dosage Modifications

Coadministration with CYP inhibitors

  • Strong CYP1A2 inhibitors: Use one-third clozapine dose
  • Moderate or weak CYP1A2 inhibitors: Monitor for adverse reactions; consider reducing clozapine dose if needed
  • CYP2D6 or CYP3A4 inhibitors: Monitor for adverse reactions; consider reducing clozapine dose if needed
  • CYP2D6 poor metabolizers: Clozapine dose reduction may be needed

Coadministration with CYP inducers

  • Strong CYP3A4 inducers: Coadministration not recommended; if the inducer is necessary, clozapine dose may need to be increased
  • Moderate or weak CYP1A2 or CYP3A4 inducers: Monitor for decreased effectiveness; consider increasing clozapine dose if necessary

Renal or hepatic impairment

  • Dose reduction may be necessary with significant renal or hepatic impairment

Dosing Considerations

Required laboratory monitoring

  • Before initiating, obtain CBC count with differential for baseline ANC; to continue treatment, ANC must be monitored regularly
  • In order to initiate treatment, ANC must be ≥1500/mm3 for the general population and ≥1000/mm3 for patients with documented benign ethnic neutropenia

Safety and efficacy not established

Lower initial dosage of 12.5-25 mg/day indicated; may be titrated more slowly than in younger adults

Elderly patients, particularly those with compromised cardiovascular functioning, may be more susceptible to orthostatic hypotension and tachycardia; anticholinergic effects are also common (constipation, confusion, urinary retention)

Next:

Interactions

Interaction Checker

and clozapine

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            >10%

            Hypersalivation (13-48%)

            Sedation/somnolence (21-46%)

            Weight gain (4-31%)

            Dizziness (14-27%)

            Tachycardia (17-25%)

            Constipation (14-25%)

            Insomnia (2-20%)

            Dizziness/vertigo (19%)

            Nausea (17%)

            Vomiting (17%)

            Dyspepsia (14%)

            Hypotension (9-13%)

            Fever (5-13%)

            1-10%

            Headache (7-10%)

            Tremor (6%)

            Syncope (6%)

            Sweating (6%)

            Dry mouth (5-6%)

            Visual disturbances (5%)

            Disturbed sleep/nightmares (4%)

            Restlessness (4%)

            Hypokinesia/akinesia (4%)

            Agitation (4%)

            Hypertension (4%)

            Abdominal discomfort/heartburn (4%)

            Seizures (3%)

            Rigidity (3%)

            Akathisia (3%)

            Confusion (3%)

            Leukopenia/neutropenia (3%)

            Fatigue (2%)

            Diarrhea (2%)

            Urinary abnormalities (2%)

            Rash (2%)

            Postmarketing Reports

            Skin: Hypersensitivity reactions: photosensitivity, vasculitis, erythema multiforme, and Stevens-Johnson Syndrome, skin pigmentation disorder

            Musculoskeletal system: Myasthenic syndrome, rhabdomyolysis, systemic lupus erythematosus

            Respiratory system: Aspiration, pleural effusion, pneumonia and lower respiratory tract infection (LRTI), which may be fatal, sleep apnea

            Central nervous system: Delirium, EEG abnormal, myoclonus, paresthesia, possible cataplexy, status epilepticus, obsessive compulsive symptoms, and post-discontinuation cholinergic rebound adverse reactions, tardive dyskinesia, neuroleptic malignant syndrome

            Cardiovascular: Atrial or ventricular tachycardia or fibrillation, periorbital edema, myocardial infarction, cardiac arrest, QT prolongation, Torsades de pointes, hypertension, mitral valve incompetence, bradycardia, cardiomyopathy

            Endocrine system: Pseudopheochromocytoma

            Gastrointestinal system: Acute pancreatitis, dysphagia, salivary gland swelling, colitis, hypersalivation, dry mouth

            Hepatobiliary: Hepatotoxicity, hepatic steatosis, hepatic necrosis, hepatic fibrosis, hepatic cirrhosis, liver injury (hepatic, cholestatic, and mixed), and liver failure

            Immune system disorders: Angioedema, leukocytoclastic vasculitis

            Urogenital: Renal failure, nocturnal enuresis, acute interstitial nephritis, priapism, retrograde ejaculation

            Hemic and lymphatic system: DVT; elevated hemoglobin/hematocrit, ESR; sepsis, pulmonary embolism, thrombocytosis, thrombocytopenia, angioedema, leukocytoclastic vasculitis, eosinophilia

            Vision disorders: Narrow-angle glaucoma

            Miscellaneous: CPK elevation, hyperuricemia, hyponatremia, weight loss

            Previous
            Next:

            Warnings

            Black Box Warnings

            Agranulocytosis

            • Available only through a restricted program called the Clozapine REMS
            • Severe neutropenia, defined as an absolute neutrophil count (ANC) <500/mm3, has been reported
            • Severe neutropenia can lead to serious infection and death
            • Before initiating, baseline ANC must be ≥1500/mm3 for the general population and ≥1000/mm3 for patients with documented benign ethnic neutropenia
            • Regularly monitor ANC during treatment
            • Advise patients to immediately report symptoms consistent with severe neutropenia or infection (eg, fever, weakness, lethargy, sore throat)

            Seizures

            • Caution with history of seizure or other factors predisposing to seizure
            • Risk is dose-related

            Myocarditis, cardiomyopathy, and mitral valve incompetence

            • Fatal myocarditis and cardiomyopathy reported; discontinue and obtain cardiac evaluation if suspected
            • Measuring brain NP levels may offer a means of monitoring to detect early, asymptomatic myocarditis
            • Generally, patients with a history of clozapine-associated myocarditis or cardiomyopathy should not be rechallenged; however, if benefit of treatment is judged to outweigh potential risks of recurrent myocarditis or cardiomyopathy, the clinician may consider rechallenging in consultation with a cardiologist, after a complete cardiac evaluation, and under close monitoring

            Orthostatic hypotension, bradycardia, syncope

            • Orthostatic hypotension, bradycardia, syncope, and cardiac arrest may occur
            • Risk is highest during initial titration period, particularly with rapid dose escalation
            • May occur with the first dose, and with doses as low as 12.5 mg/day
            • Caution with history of cardiovascular or cerebrovascular disease or conditions predisposing to hypotension

            Increased mortality in elderly with dementia-related psychosis

            • Not approved for dementia-related psychosis; patients with dementia-related psychosis who are treated with antipsychotic drugs are at increased risk of death, as shown in short-term controlled trials; deaths in these trials appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature

            Contraindications

            Hypersensitivity (eg, photosensitivity, vasculitis, erythema multiforme, Stevens-Johnson syndrome)

            Cautions

            Increased risk of dose-related seizures

            Eosinophilia (blood eosinophil count >700/mm3) reported; associated in some patients with myocarditis, pancreatitis, hepatitis, colitis, and nephritis; organ involvement could be consistent with a drug reaction with eosinophilia and systemic symptoms syndrome (DRESS)

            Increased risk of cerebrovascular adverse events reported with some atypical antipsychotics (mechanism unknown)

            FDA warning regarding off-label use for dementia-related psychosis in elderly patients; increased risk of death

            Antipsychotic drugs can cause the potentially fatal symptom complex referred to as neuroleptic malignant syndrome (NMS); if NMS occurs, immediately discontinue antipsychotic drug, and other drugs not essential to therapy; implement intensive symptomatic treatment and medical monitoring

            Possible QT prolongation; use with caution in patients with history of long QT syndrome or other conditions that may increase risk (eg, hypokalemia, hypomagnesemia)

            Severe, life threatening, and in some cases fatal hepatotoxicity including hepatic failure, hepatic necrosis, and hepatitis reported in post marketing studies; monitor for appearance of signs and symptoms of hepatotoxicity such as fatigue, malaise, anorexia, nausea, jaundice, bilirubinemia, coagulopathy, and hepatic encephalopathy; perform serum tests for liver injury and consider permanently discontinuing treatment if hepatitis or transaminase elevations combined with other systemic symptoms are due to clozapine

            Transient fever reported; peak incidence is within first 3 weeks of treatment; although this fever is generally benign and self-limited, it may necessitate discontinuing treatment since fever can be associated with an increase or decrease in WBC count; evaluate patients with fever to rule out severe neutropenia or infection; consider possibility of NMS

            Pulmonary embolism (PE) and DVT reported; unclear whether PE and DVT can be attributed to clozapine

            Myocarditis, cardiomyopathy and mitral valve incompetence

            • Myocarditis, cardiomyopathy, and mitral valve incompetence reported, including fatalities; discontinue and obtain cardiac evaluation upon suspicion of myocarditis or cardiomyopathy
            • Consider the possibility of myocarditis or cardiomyopathy in patients receiving therapy who present with chest pain, dyspnea, persistent tachycardia at rest, palpitations, fever, flu-like symptoms, hypotension, other signs or symptoms of heart failure, or electrocardiographic findings (low voltages, ST-T abnormalities, arrhythmias, right axis deviation, and poor R wave progression)
            • Myocarditis most frequently presents within first two months of clozapine treatment; symptoms generally occur later than clozapine-associated myocarditis and usually after 8 weeks of treatment
            • However, myocarditis and cardiomyopathy can occur at any period during treatment; it is common for nonspecific flu- like symptoms such as malaise, myalgia, pleuritic chest pain, and low-grade fevers to precede more overt signs of heart failure
            • Typical laboratory findings include elevated troponin I or T, elevated creatinine kinase-MB, peripheral eosinophilia, and elevated C-reactive protein (CRP)
            • Chest roentgenogram may demonstrate cardiac silhouette enlargement, and cardiac imaging (echocardiogram, radionucleotide studies, or cardiac catheterization) may reveal evidence of left ventricular dysfunction
            • In patients who are diagnosed with cardiomyopathy while taking clozapine mitral valve incompetence has been reported; these cases reported either mild or moderate mitral regurgitation on two-dimensional echocardiography
            • In patients with suspected cardiomyopathy, consider a 2D-echo Doppler examination to identify mitral valve incompetence

            Neutropenia

            • Only available through a restricted access program because of risk for neutropenia (ie, low ANC); patients must be registered, prescriber must enroll and complete training, and pharmacies dispensing clozapine must be certified and complete training
            • Severe neutropenia (ANC <500/mm³) occurs in a small percentage of patients and is associated with increased risk of serious and potentially fatal infections; risk is greatest during the first 18 weeks of treatment and then declines; see prescribing information for detailed information regarding monitoring ANC, including patients with benign ethnic neutropenia
            • Benign transient elevation of temperature reported, peaking within first 3 weeks of treatment (rule out agranulocytosis, infection, NMS)

            Metabolic changes

            • Increased risk of hyperglycemia and diabetes; in some cases, hyperglycemia concomitant with use of atypical antipsychotics has been associated with esophageal dysmotility, ketoacidosis, hyperosmolar coma, or death; monitor blood glucose of high-risk patients
            • Dyslipidemia and weight gain reported with atypical antipsychotics

            Anticholinergic effects

            • Potent anticholinergic effects can occur that can result in CNS and peripheral anticholinergic toxicity
            • Caution with narrow-angle glaucoma, concomitant anticholinergic medications, prostatic hypertrophy, or other conditions in which anticholinergic effects can lead to significant adverse reactions
            • Impaired core body temperature regulation may occur; caution with strenuous exercise, dehydration, heat exposure, and concomitant medication possessing anticholinergic effects
            • Gastrointestinal adverse reactions, including constipation, intestinal obstruction, fecal impaction, and paralytic ileus reported; such reactions can be fatal
            • Constipation should be initially treated by ensuring adequate hydration and use of ancillary therapy (eg, bulk laxatives); consult with gastroenterologist in more serious cases
            • Evaluate bowel function before initiating treatment
            • Instruct patients on preventive measures and to seek medical help if constipation occurs

            Cognitive and motor abilities

            • May cause somnolence, postural hypotension, motor and sensory instability, which may lead to falls and, consequently, fractures or other injuries; for patients with diseases, conditions, or medications that could exacerbate these effects, complete fall risk assessments when initiating antipsychotic treatment and recurrently for patients on long- term antipsychotic therapy
            • May cause CNS depression, which may impair physical or mental abilities; caution patients about performing tasks that require mental alertness

            Tardive dyskinesia

            • Tardive dyskinesia (TD) has occurred with antipsychotic drugs
            • Syndrome consists of potentially irreversible, involuntary, dyskinetic movements
            • Risk of TD and the likelihood that it will become irreversible are believed to increase with greater durations of treatment and higher total cumulative doses; however, the syndrome can develop after relatively brief treatment periods at low doses
            • Prescribe drug in a manner that is most likely to minimize TD risk
            • Use the lowest effective dose and the shortest duration necessary to control symptoms
            • Periodically assess need for continued treatment; consider discontinuing treatment if TD occurs
            • Some patients may require treatment despite the presence of the syndrome
            • There is no known treatment for TD; however, the syndrome may remit partially or completely if treatment is discontinued

            Drug interaction overview

            • CYP inhibitors and inducers
              • Clozapine is a substrate for many cytochrome P450 isozymes, in particular CYP1A2, CYP2D6, and CYP3A4
              • Clozapine dosage modification may be required if coadministered with drugs that inhibit or induce metabolism of clozapine (eg, CYP 1A2, 2D6, and 3A4 inhibitors)
            • QT prolongation
              • Clozapine associated with QT prolongation
              • Caution if coadministered with other drugs that prolong QT interval
            • CYP2D6 substrates
              • Clozapine inhibits CYP2D6
              • Coadministration with CYP2D6 substrates can increase levels of these substrate; lower dose of CYP2D6 substrate may be required
            • Anticholinergic drugs
              • Caution if coadministered with other drugs that elicit anticholinergic effects
              • Monitor carefully for additive anticholinergic effects
            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy

            There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to atypical antipsychotics, including clozapine, during pregnancy; health care providers are encouraged to register patients by contacting the National Pregnancy Registry for Atypical Antipsychotics at 1-866-961-2388 or visit http://womensmental health.org/clinical-and-research-programs/pregnancyregistry/

            Neonates exposed to antipsychotic drugs during the third trimester are at risk for extrapyramidal and/or withdrawal symptoms following delivery; overall, available data from published epidemiologic studies of pregnant women exposed to clozapine have not established a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes; there are risks to the mother associated with untreated schizophrenia and with exposure to antipsychotics, during pregnancy

            Animal data

            • In animal reproduction studies, no adverse developmental effects were observed with drug administered to pregnant rats or rabbits during period of organogenesis, or to pregnant rats during pregnancy and lactation, at doses up to approximately 0.4 and 0.9 times the maximum recommended human dose (MRHD) of 900 mg/day, for rats and rabbits respectively, based on mg/m2 body surface area
            • There is risk to mother from untreated schizophrenia, including increased risk of relapse, hospitalization, and suicide; schizophrenia is associated with increased adverse perinatal outcomes, including preterm birth; it is not known if this is a direct result of the illness or other comorbid factors
            • Extrapyramidal and/or withdrawal symptoms, including agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, and feeding disorder reported in neonates exposed to antipsychotic drugs during third trimester of pregnancy; these symptoms have varied in severity; monitor neonates for extrapyramidal and/or withdrawal symptoms and manage symptoms appropriately; some neonates recovered within hours or days without specific treatment; others required prolonged hospitalization

            Lactation

            Clozapine is present in human milk; there are reports of sedation and a report of agranulocytosis in an infant exposed to clozapine through human milk; there is no information on effects of clozapine on milk production; the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for therapy and any potential adverse effects on breastfed-child from drug or from underlying maternal condition

            Infants exposed to drug should be monitored for excess sedation

            Pregnancy Categories

            A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA: Information not available.

            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Demonstrates weak D2-receptor and D1-receptor blocking activity, but noradrenolytic, anticholinergic, antihistaminic, and arousal reaction inhibiting effects are significant; also possesses antiserotoninergic (5-HT1C, 5-HT2, 5-HT3) properties

            Affinity for mesolimbic dopamine D4 receptor accounts for striking effects in control of behavioral and psychiatric symptoms with low incidence of EPS; histamine receptor blockade accounts for increased incidence of sleep disturbances

            Absorption

            Bioavailability: 50-60%

            Onset: 15 min

            Duration: 4-12 hr

            Peak plasma time: 1.5-2.5 hr

            Peak plasma concentration: 102-771 ng/mL

            Distribution

            Protein bound: 97%

            Vd: 4.67 L/kg

            Metabolism

            Metabolized by hepatic P450 enzyme CYP1A2, N-demethylation, N-oxidation, 3'-carbon oxidation, epoxidation of chlorine-containing aromatic ring, substitution of chlorine by hydroxyl or thiomethyl groups, and sulfur oxidation; also CYP2D6 and CYP3A4

            Metabolites: Norclozapine

            Elimination

            Half-life: 12 hr

            Blood clearance: 250 mL/min

            Total plasma clearance: 217 mL/min

            Excretion: Urine (50%), feces (30%)

            Previous
            Next:

            Administration

            Oral Administration

            May take with or without food

            Minimize risk of orthostatic hypotension, bradycardia, and syncope by using low starting dose, gradual titration schedule, and divided dosages

            Storage

            Store at temperature not exceeding 30ºC (86ºF)

            Previous
            Next:

            Images

            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
            Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.